Atai Life Sciences Sees Positive Study Results for EMP-01

The four-cohort, single-ascending dose, randomized, double-blind, placebo-controlled study enrolled 32 healthy participants who received 75mg, 125mg, 175mg or 225mg of EMP-01.

EMP-01 was well-tolerated, and treatment-related adverse events were all expected and generally dose dependent. There were no study discontinuations, and no serious or severe adverse events were observed in the study.

Non-clinically significant increases in blood pressure and heart rate were observed, though such changes showed limited dose dependency. The peak body temperatures observed fell within the normal range.

Write to Chris Wack at [email protected]